Advancing new O-antigen-based Shigella vaccines is critically dependent on development of an international standard serum and harmonized ELISA, demonstration of field efficacy in young children in low- and middle-income countries, and early engagement with regulators and policy makers.
Journal article
2022-05-04T00:00:00+00:00
225
1500 - 1503
3
Shigella, CHIM, LMICs, global health, vaccines, Dysentery, Bacillary, Enterotoxigenic Escherichia coli, Global Health, Humans, Shigella Vaccines, Vaccines